Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2021 06:44 ET | Source: Biogen Inc.

Update on Regulatory Submission for Aducanumab in the European Union

CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...
December 16, 2021 07:00 ET | Source: Biogen Inc.

Update on the Phase 4 Confirmatory Study of ADUHELM®

CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today provided an important update on the continuing progress of the Phase 4...
December 14, 2021 07:00 ET | Source: Biogen Inc.

Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience

Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurologyBiogen to gain exclusive rights to TheraPanacea...
November 17, 2021 07:30 ET | Source: Biogen Inc.

Update on Regulatory Review of Aducanumab in the European Union

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing Authorization...
November 16, 2021 09:20 ET | Source: Biogen Inc.

The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral...
November 15, 2021 19:44 ET | Source: Biogen Inc.

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that Alfred “Al” W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from...
November 15, 2021 07:30 ET | Source: Biogen Inc.

Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year

Biogen earns top ESG leadership scores on areas including Innovation Management and Climate Strategy, highlighting efforts to address urgent and long-term challenges facing humanityIn 2021, Biogen...
November 11, 2021 17:10 ET | Source: Biogen Inc.

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

In a pre-specified analysis, ADUHELM significantly lowered plasma p-tau181, a biomarker of the hallmark tau tangles in Alzheimer’s disease, in both Phase 3 trials in a dose- and time-dependent manner...
November 03, 2021 07:30 ET | Source: Biogen Inc.

Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Late breaker will show ADUHELM™ effect on plasma pTau181 reduction, and its correlation with amyloid beta and slowing cognitive and functional decline.Additional phase 3b late breaker data will shed...
October 17, 2021 16:20 ET | Source: Biogen Inc.

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of...